Research and diagnosis of infectious Risk Group 3 (RG3) biological agents require specially designed Biosafety Level-3 (BSL-3) laboratories, operating procedures and practices to ensure the personal, communal, and environmental protection. The Biosafety Level-3 (BSL-3) Core Facility established in November 2014 at the NUS Yong Loo Lin School of Medicine (NUS Medicine) is the largest research-focused biocontainment facility in Singapore. The facility supports research and diagnostic work involving a range of RG3 biological agents. It is certified by the Biosafety Branch of the Singapore Ministry of Health and the Animal & Veterinary Service (AVS), NParks, Singapore.
The state-of-the-art 650m2 facility situated in the Centre for Translational Medicine (MD6 building) on the NUS Kent Ridge campus, is equipped with a range of laboratory equipment with advanced technologies (including flow cytometers, aerosolization machine for establishing infectious disease mouse models and PET/CT imaging to evaluate various organ and tissue functions in animals). Associate Professor Justin Chu Jang Hann serves as the Director of the BSL-3 Core Facility, directing a team of skilled personnel who operates the facility as well as assists in performing in vitro and in vivo work with RG3 pathogens. Currently, the facility is open to researchers from NUS and other non-NUS institutions, including scientists from outside Singapore, to conduct their research on RG3 biological agents. It also supports the Singapore National Public Health Laboratory activities such as RG3 pathogen surveillance and national preparedness for effective disease outbreak management programme.
To be a leading global centre of excellence for high-containment infectious disease translational research.
- To provide a state-of-the-art BSL-3/ABSL-3 research environment and promote collaborations for scientists and clinicians
- To train laboratory users in the safe handling of biological agents and toxins that are in compliance with local regulations
- To ensure regulatory compliance
- To promote biosafety/biosecurity through continuous education and training
- To stimulate development of new diagnostics, therapeutics, vaccines and high-impact translational and public health research